ArticleJournal of clinical medicine2024
Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Incremental effects of vericiguat added to sacubitril/valsartan in heart failure with nonpreserved ejection fraction: a real-world study.International journal of cardiology. Heart & vasculature · 2026Article
- One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain.ESC heart failure · 2026Observational
- Vericiguat: A New Horizon for Heart Failure Treatment.Reviews in cardiovascular medicine · 2026Review
- One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study.International journal of cardiology. Heart & vasculature · 2026Article
- Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management.Cardiology and therapy · 2026Article
- Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.American heart journal plus : cardiology research and practice · 2026Article
- Efficacy and Safety of Vericiguat in a Real-life Population with Heart Failure after 1 Year of Treatment: The VERITA Study.Cardiac failure review · 2026Article
- The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.Reviews in cardiovascular medicine · 2025Review
- Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies.Frontiers in cardiovascular medicine · 2025Review
- Minute Ventilation/Carbon Dioxide Production Slope Could Predict Short- and Long-Term Prognosis of Patients After Acute Decompensated Heart Failure.Life (Basel, Switzerland) · 2024Article
- Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.